{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T11:06:38Z","timestamp":1774868798816,"version":"3.50.1"},"publisher-location":"Cham","reference-count":129,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783319588094","type":"print"},{"value":"9783319588117","type":"electronic"}],"license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017]]},"DOI":"10.1007\/978-3-319-58811-7_14","type":"book-chapter","created":{"date-parts":[[2017,9,27]],"date-time":"2017-09-27T14:48:09Z","timestamp":1506523689000},"page":"385-409","source":"Crossref","is-referenced-by-count":34,"title":["PDE Inhibitors for the Treatment of Schizophrenia"],"prefix":"10.1007","author":[{"given":"Gretchen L.","family":"Snyder","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberly E.","family":"Vanover","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,9,28]]},"reference":[{"key":"14_CR1","doi-asserted-by":"crossref","first-page":"30423","DOI":"10.1074\/jbc.M111.266379","volume":"286","author":"R Acin-Perez","year":"2011","unstructured":"Acin-Perez R, Gunnewig K, Gertz M, Zoidl G, Ramos L, Buck J, Levin LR, Rassow J, Manfredi G, Steegborn C. A phosphodiesterase 2A isoform localized to mitochrondria regulates respiration. J Biol Chem. 2011;286:30423\u201332.","journal-title":"J Biol Chem"},{"key":"14_CR2","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1101\/lm.040162.115","volume":"23","author":"S Akkerman","year":"2016","unstructured":"Akkerman S, Blokland A, Prickaerts J. Possible overlapping time frames of acquisition and consolidation phases in object memory processes: a pharmacological approach. Learn Mem. 2016;23:29\u201337.","journal-title":"Learn Mem"},{"key":"14_CR3","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.bmcl.2012.11.077","volume":"23","author":"JI Andres","year":"2013","unstructured":"Andres JI, Buijnsters P, De Angelis M, Langlois X, Rombouts F, Trabanco AA, Vanhoof G. Discovery of a new series of [1,2,4]triazolo[4,3-a]quinoxalines as dual phosphodiesterase 2\/phosphodiesterase 10(PDE2\/PDE10) inhibitors. Bioorg Med Chem Lett. 2013;23:785\u201390.","journal-title":"Bioorg Med Chem Lett"},{"key":"14_CR4","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/nrn2648","volume":"10","author":"AF Arnsten","year":"2009","unstructured":"Arnsten AF. Stress signaling pathways that impair prefrontal cortex structure and function. Nat Rev Neurosci. 2009;10:410\u201322.","journal-title":"Nat Rev Neurosci"},{"key":"14_CR5","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.schres.2011.10.015","volume":"134","author":"SM August","year":"2012","unstructured":"August SM, Kiwanuka JN, McMahon RP, Gold JM. The MATRICS consensus cognitive battery (MCCB): clinical and cognitive correlates. Schizophr Res. 2012;134:76\u201382.","journal-title":"Schizophr Res"},{"key":"14_CR6","doi-asserted-by":"crossref","first-page":"5280","DOI":"10.1073\/pnas.96.9.5280","volume":"96","author":"ME Bach","year":"1999","unstructured":"Bach ME, Barad M, Son H, Zhou M, YF L, Shih R, Mansuy I, Hawkins RD, Kandel ER. Age-related defects in spatial memory are correlated with defects in the late phase of hippocampal long-term potentiation in vitro and are attenuated by drugs that enhance the cAMP signaling pathway. Proc Natl Acad Sci U S A. 1999;96:5280\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"14_CR7","doi-asserted-by":"crossref","first-page":"15020","DOI":"10.1073\/pnas.95.25.15020","volume":"95","author":"M Barad","year":"1998","unstructured":"Barad M, Bourtchouladze R, Winder DG, Golan H, Kandel E. Rolipram, a type IV-specific phosphodiesterase inhibitor, facilitates the establishment of long-lasting long-term potentiation and improves memory. Proc Natl Acad Sci U S A. 1998;95:15020\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"14_CR8","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1038\/nn.2153","volume":"11","author":"HS Bateup","year":"2008","unstructured":"Bateup HS, Svenningsson P, Kuroiwa M, Gong S, Nishi A, Heintz N, Greengard P. Cell type-specific regulation of DARPP-32 phosphorylation by psychostimulant and antipsychotic drugs. Nat Neurosci. 2008;11:932\u20139.","journal-title":"Nat Neurosci"},{"key":"14_CR9","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1152\/physrev.1995.75.4.725","volume":"75","author":"JA Beavo","year":"1995","unstructured":"Beavo JA. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev. 1995;75:725\u201348.","journal-title":"Physiol Rev"},{"key":"14_CR10","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1038\/nrm911","volume":"3","author":"JA Beavo","year":"2002","unstructured":"Beavo JA, Brunton LL. Cyclic nucleotide research\u2014still expanding after half a century. Nat Rev Mol Cell Biol. 2002;3:710\u20138.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"14_CR11","doi-asserted-by":"crossref","first-page":"18676","DOI":"10.1016\/S0021-9258(19)37014-0","volume":"267","author":"JK Bentley","year":"1992","unstructured":"Bentley JK, Kadlecek A, Sherbert CH, Seger D, Sonnenburg WK, Charbonneau H, et al. Molecular cloning of cDNA encoding a \u201c63\u201d-kDa calmodulin-stimulated phosphodiesterase from bovine brain. J Biol Chem. 1992;267:18676\u201382.","journal-title":"J Biol Chem"},{"key":"14_CR12","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.neuropharm.2004.07.040","volume":"47","author":"FG Boess","year":"2004","unstructured":"Boess FG, Hendrix M, van der Staay FJ, Erb C, Schreiber R, van Staveren W, de Vente J, Prickaerts J, Blokland A, Koenig G. Inhibition of phosphodiesterase 2 increases neuronal cGMP, synaptic plasticity and memory performance. Neuropharmacology. 2004;47:1081\u201392.","journal-title":"Neuropharmacology"},{"key":"14_CR13","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1101\/lm.5.4.365","volume":"5","author":"R Bourtchouladze","year":"1998","unstructured":"Bourtchouladze R, Abel T, Berman N, Gordon R, Lapidus K, Tully T. Different training procedures recruit either one of two critical periods for contextual memory consolidation, each of which requires protein synthesis and PKA. Learn Mem. 1998;5:365\u201374.","journal-title":"Learn Mem"},{"issue":"7","key":"14_CR14","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.cellsig.2015.09.019","volume":"28","author":"NJ Brandon","year":"2015","unstructured":"Brandon NJ. Uncovering the function of disrupted in schizophrenia 1 through interactions with the cAMP phosphodiesterase PDE4: contributions of the Houslay lab to molecular psychiatry. Cell Signal. 2015;28(7):749\u201352. doi: 10.1016\/j.cellsig.2015.09.019 .","journal-title":"Cell Signal"},{"key":"14_CR15","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.mcn.2003.09.009","volume":"25","author":"NJ Brandon","year":"2004","unstructured":"Brandon NJ, Handford EJ, Schurov I, Rain JC, Pelling M, Duran-Jimeniz B, Camargo LM, Oliver KR, Beher D, Shearman MS, Whiting PJ. Disrupted in schizophrenia 1 and Nudel form a neurodevelopmentally regulated protein complex: implications for schizophrenia and other major neurological disorders. Mol Cell Neurosci. 2004;25:42\u201355.","journal-title":"Mol Cell Neurosci"},{"key":"14_CR16","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1001\/archpsyc.1991.01810270051007","volume":"48","author":"A Breier","year":"1991","unstructured":"Breier A, Schreiber JL, Dyer J, Pickar D. National Institute of Mental Health longitudinal study of chronic schizophrenia. Prognosis and predictors of outcome. Arch Gen Psychiatry. 1991;48:239\u201346.","journal-title":"Arch Gen Psychiatry"},{"key":"14_CR17","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/nbt.1598","volume":"28","author":"AB Burgin","year":"2010","unstructured":"Burgin AB, Magnusson OT, Singh J, Witte P, Staker BL, Bjornsson JM, Thorsteindottir M, Hrafnsdottir S, Hagen T, Kiselyov AS, Stewart LJ, Gurney ME. Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety. Nat Biotechnol. 2010;28:63\u201370.","journal-title":"Nat Biotechnol"},{"key":"14_CR18","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.schres.2013.02.026","volume":"146","author":"C Burton","year":"2013","unstructured":"Burton C, Vella L, Harvey PD, Patterson TL, Heaton RK, Twamley EW. Factor structure of the MATRICS consensus cognitive battery (MCCB) in schizophrenia. Schizophr Res. 2013;146:244\u20138.","journal-title":"Schizophr Res"},{"key":"14_CR19","doi-asserted-by":"crossref","first-page":"9027","DOI":"10.1523\/JNEUROSCI.1635-10.2010","volume":"30","author":"E Charych","year":"2010","unstructured":"Charych E, Jiang LX, Lo F, Sullivan K, Brandon NJ. Interplay of palmitoylation and phosphorylation in the trafficking and localizaiton of phosphodiesterase 10A: implications for the treatment of schizophrenia. J Neurosci. 2010;30:9027\u201337.","journal-title":"J Neurosci"},{"key":"14_CR20","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1002\/neu.480280109","volume":"28","author":"JA Cherry","year":"1995","unstructured":"Cherry JA, Davis RL. A mouse homolog of dunce, a gene important for learning and memory in drosophila, is preferentially expressed in olfactory receptor neurons. J Neurobiol. 1995;28:102\u201313.","journal-title":"J Neurobiol"},{"key":"14_CR21","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/(SICI)1096-9861(19990503)407:2<287::AID-CNE9>3.0.CO;2-R","volume":"407","author":"JA Cherry","year":"1999","unstructured":"Cherry JA, Davis RL. Cyclic AMP phosphodiesterases are localized in regions of the mouse brain associated with reinforcement, movement, and affect. J Comp Neurol. 1999;407:476\u2013509.","journal-title":"J Comp Neurol"},{"key":"14_CR22","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1038\/sj.npp.1300490","volume":"29","author":"Y Chudasama","year":"2004","unstructured":"Chudasama Y, Robbins TW. Dopaminergic modulation of visual attention and working memory in the rodent prefrontal cortex. Neuropsychopharmacology. 2004;29:1628\u201336.","journal-title":"Neuropsychopharmacology"},{"key":"14_CR23","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.neuron.2007.04.015","volume":"54","author":"SJ Clapcote","year":"2007","unstructured":"Clapcote SJ, Lipina TV, Millar JK, Mackie S, Christie S, Ogawa F, Lerch JP, Trimble K, Uchiyama M, Sakuraba Y, Kaneda H, Shiroishi T, Houslay MD, Henkelman RM, Sled JG, Gondo Y, Porteous DJ, Roder JC. Behavioral phenotypes of DISC1 missense mutations in mice. Neuron. 2007;54:387\u2013402.","journal-title":"Neuron"},{"key":"14_CR24","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/ng847","volume":"30","author":"EL Coghill","year":"2002","unstructured":"Coghill EL, Hugill A, Parkinson N, Davison C, Glenister P, Clements S, Hunter J, Cox RD, Brown SD. A gene-driven approach to the identification of ENU mutants in the mouse. Nat Genet. 2002;30:255\u20136.","journal-title":"Nat Genet"},{"key":"14_CR25","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S0962-8924(99)01558-5","volume":"9","author":"M Colledge","year":"1999","unstructured":"Colledge M, Scott JD. AKAPs: from structure to function. Trends Cell Biol. 1999;9:216\u201321.","journal-title":"Trends Cell Biol"},{"key":"14_CR26","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1146\/annurev.biochem.76.060305.150444","volume":"76","author":"M Conti","year":"2007","unstructured":"Conti M, Beavo J. Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu Rev Biochem. 2007;76:481\u2013511.","journal-title":"Annu Rev Biochem"},{"key":"14_CR27","doi-asserted-by":"crossref","first-page":"5493","DOI":"10.1074\/jbc.R200029200","volume":"278","author":"M Conti","year":"2003","unstructured":"Conti M, Richter W, Mehats C, Livera G, park JY, Jin C. Cyclic AMP-specific PDE4 phosphodiesterases as critical components of cyclic AMP signaling. J Biol Chem. 2003;278:5493\u20136.","journal-title":"J Biol Chem"},{"key":"14_CR28","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1369\/jhc.6A6930.2006","volume":"54","author":"TM Coskran","year":"2006","unstructured":"Coskran TM, Morton D, Menniti FS, Adamowicz WO, Kleiman RJ, Ryan AM, et al. Immunohistochemical localization of phosphodiesterase 10A in multiple mammalian species. J Histochem Cytochem. 2006;54:1205\u201313.","journal-title":"J Histochem Cytochem"},{"key":"14_CR29","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1126\/science.194.4264.546","volume":"194","author":"I Creese","year":"1976","unstructured":"Creese I, Burt DR, Snyder SH. Dopamine receptors and average clinical doses. Science. 1976;194:546.","journal-title":"Science"},{"key":"14_CR30","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1176\/ajp.148.11.1474","volume":"148","author":"KL Davis","year":"1991","unstructured":"Davis KL, Kahn RS, Ko G, Davidson M. Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry. 1991;148:1474\u201386.","journal-title":"Am J Psychiatry"},{"key":"14_CR31","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1006\/nlme.1996.0072","volume":"66","author":"BD Devan","year":"1996","unstructured":"Devan BD, Goad EH, Petri HL. Dissociation of hippocampal and striatal contributions to spatial navigation in the water maze. Neurobiol Learn Mem. 1996;66:305\u201322.","journal-title":"Neurobiol Learn Mem"},{"key":"14_CR32","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1523\/JNEUROSCI.19-07-02789.1999","volume":"19","author":"BD Devan","year":"1999","unstructured":"Devan BD, White NM. Parallel information processing in the dorsal striatum; relation to hippocampal function. J Neurosci. 1999;19:2789\u201398.","journal-title":"J Neurosci"},{"key":"14_CR33","doi-asserted-by":"crossref","first-page":"3813","DOI":"10.2174\/1381612821666150605110941","volume":"21","author":"MV Duinen","year":"2015","unstructured":"Duinen MV, Reneerkens OA, Lambrecht L, Sambeth A, Rutten BP, JV O, Blokland A, Prickaerts J. Treatment of cognitive impairment in schizophrenia: potential value of phosphodiesterase inhibitors in prefrontal dysfunction. Curr Pharm Des. 2015;21:3813\u201328.","journal-title":"Curr Pharm Des"},{"key":"14_CR34","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/j.1601-183X.2006.00209.x","volume":"5","author":"LA Ehrman","year":"2006","unstructured":"Ehrman LA, Williams MT, Schaefer TL, Gudelsky GA, Reed TM, Fienberg AA, Greengard P, Vorhees CV. Phosphodiesterase 1B differentially modulates the effects of methamphetamine on locomotor activity and spatial learning through DARPP-32-dependent pathways: evidence from PDE1B-DARPP-32 double knockout mice. Genes Brain Beh. 2006;5:540\u201351.","journal-title":"Genes Brain Beh"},{"issue":"7","key":"14_CR35","doi-asserted-by":"crossref","first-page":"3702","DOI":"10.1073\/pnas.97.7.3702","volume":"97","author":"L Fawcett","year":"2000","unstructured":"Fawcett L, Baxendale R, Stacey P, McGrouther C, Harrow I, Soderling S, Hetman J, Beavo JA, Phillips SC. Molecular cloning and characterization of a distinct human phosphodiesterase gene family: PDE11A. Proc Natl Acad Sci U S A. 2000;97(7):3702.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"14_CR36","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/syn.21840","volume":"69","author":"D Fern\u00e1ndez-Fern\u00e1ndez","year":"2015","unstructured":"Fern\u00e1ndez-Fern\u00e1ndez D, Rosenbrock H, Kroker KS. Inhibition of PDE2A, but not PDE9A, modulates presynaptic short-term plasticity measured by paired-pulse facilitation in the CA1 region of the hippocampus. Synapse. 2015;69:484\u201396.","journal-title":"Synapse"},{"key":"14_CR37","doi-asserted-by":"crossref","first-page":"15559","DOI":"10.1074\/jbc.273.25.15559","volume":"273","author":"DA Fischer","year":"1998","unstructured":"Fischer DA, Smith JF, Pillar JS, St. Denis SH, Cheng JB. Isolation and characterization of PDE9A, a novel human cGMP-specific phosphodiesterase. J Biol Chem. 1998;273:15559\u201364.","journal-title":"J Biol Chem"},{"key":"14_CR38","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1007\/s00213-005-0157-6","volume":"183","author":"PJ Fletcher","year":"2005","unstructured":"Fletcher PJ, Tenn CC, Rizos Z, Lovic V, Kapur S. Sensitization to amphetamine, but not PCP, impairs attentional set shifting: reversal by a D1 receptor agonist injected into the medial prefrontal cortex. Psychopharmacology. 2005;183:190\u2013200.","journal-title":"Psychopharmacology"},{"key":"14_CR39","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.cellsig.2013.12.003","volume":"26","author":"D Fox 3rd","year":"2014","unstructured":"Fox D 3rd, Burgin AB, Gurney ME. Structural basis for the design of selective phosphodiesterase 4B inhibitors. Cell Signal. 2014;26:657\u201363.","journal-title":"Cell Signal"},{"key":"14_CR40","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1152\/physrev.00030.2010","volume":"91","author":"SH Francis","year":"2011","unstructured":"Francis SH, Blount MA, Corbin JD. Mammalian cyclic nucleotide phosphodiesterases: molecular mechanisms and physiological functions. Physiol Rev. 2011;91:651\u201390.","journal-title":"Physiol Rev"},{"key":"14_CR41","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1046\/j.1432-1327.1999.00963.x","volume":"266","author":"K Fujishige","year":"1999","unstructured":"Fujishige K, Kotera J, Omori K. Striatum- and testis-specific phosphodiesterase PDE10A isolation and characterization of a rat PDE10A. Eur J Biochem. 1999;266:1118\u201327.","journal-title":"Eur J Biochem"},{"key":"14_CR42","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1038\/tp.2013.104","volume":"3","author":"NJ Gamo","year":"2013","unstructured":"Gamo NJ, Dugue A, Paspalas CD, Kata A, Fine R, Boven L, Bryan C, Lo T, Anighoro K, Bermudez L, Peng K, Annor A, Raja A, Mansson E, Taylor SR, Patel K, Simen AA, Arnsten AFT. Role od disrupted in schizophrenia 1 (DISC1) in stress-induced prefrontal cognitive dysfunction. Transl Psychiatry. 2013;3:e328. doi: 10.1038\/tp.2013.104 .","journal-title":"Transl Psychiatry"},{"key":"14_CR43","first-page":"3","volume":"174","author":"PS Goldman-Rakic","year":"2004","unstructured":"Goldman-Rakic PS, Castner SA, Svensson TH, Siever LJ, Williams GV. Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction. Psychopharmacology. 2004;174:3\u201316.","journal-title":"Psychopharmacology"},{"key":"14_CR44","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1124\/jpet.109.155994","volume":"331","author":"SM Grauer","year":"2009","unstructured":"Grauer SM, Pulito VL, Navarra RL, Kelly MP, Graf R, Langen B, Logue S, Brennan J, Jiang L, Charych E, Egerland U, Liu F, Marquis KL, Malamas M, Hage T, Comery TA, Brandon NJ. Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia. J Pharmacol Exp Ther. 2009;331:574\u201390.","journal-title":"J Pharmacol Exp Ther"},{"key":"14_CR45","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1176\/ajp.153.3.321","volume":"153","author":"MF Green","year":"1996","unstructured":"Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry. 1996;153:321\u201330.","journal-title":"Am J Psychiatry"},{"key":"14_CR46","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.biopsych.2004.06.023","volume":"56","author":"MF Green","year":"2004","unstructured":"Green MF, Nuechterlein KH, Gold JM, Barch DM, Cohen J, Essock S, et al. Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria. Biol Psychiatry. 2004;56:301\u20137.","journal-title":"Biol Psychiatry"},{"key":"14_CR47","doi-asserted-by":"crossref","first-page":"4031","DOI":"10.1016\/j.bmcl.2014.06.002","volume":"24","author":"TJ Hagen","year":"2014","unstructured":"Hagen TJ, Mo X, Burgin AB, Fox D 3rd, Zhang Z, Gurney ME. Discovery of triazines as selective PDE4B versus PDE4D inhibitors. Bioorg Med Chem Lett. 2014;24:4031\u20134.","journal-title":"Bioorg Med Chem Lett"},{"issue":"3","key":"14_CR48","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s11065-009-9103-4","volume":"19","author":"PD Harvey","year":"2009","unstructured":"Harvey PD. Pharmacological cognitive enhancement in schizophrenia. Neuropsychol Rev. 2009;19(3):24\u201335.","journal-title":"Neuropsychol Rev"},{"key":"14_CR49","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1176\/ajp.156.9.1336","volume":"156","author":"AL Hoff","year":"1999","unstructured":"Hoff AL, Sakuma M, Wieneke M, Horon R, Kushner M, DeLisi LE. Longitudinal neuropsychological follow-up study of patients with first-episode schizophrenia. Am J Psychiatry. 1999;156:1336\u201341.","journal-title":"Am J Psychiatry"},{"key":"14_CR50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/bj20021698","volume":"370","author":"MD Houslay","year":"2003","unstructured":"Houslay MD, Adams DR. PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization. Biochem J. 2003;370:1\u201318.","journal-title":"Biochem J"},{"key":"14_CR51","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/S1359-6446(05)03622-6","volume":"10","author":"MD Houslay","year":"2005","unstructured":"Houslay MD, Schaefer P, Zhang KY. Keynote review: phosphodiesterase-4 as a therapeutic target. Drug Discov Today. 2005;10:1503\u201319.","journal-title":"Drug Discov Today"},{"key":"14_CR52","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/sj.mp.4001551","volume":"9","author":"D Javitt","year":"2004","unstructured":"Javitt D. Glutamate as a therapeutic target in psychiatric disorders. Mol Psychiatry. 2004;9:984\u201397.","journal-title":"Mol Psychiatry"},{"key":"14_CR53","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1126\/science.277.5328.953","volume":"277","author":"J Jentsch","year":"1997","unstructured":"Jentsch J, Redmond D, Elsworth J, Taylor J, Youngren K, Roth R. Enduring cognitive deficits and cortical dopamine dysfunction in monkeys after long-term administration of phencyclidine. Science. 1997;277:953\u20135.","journal-title":"Science"},{"key":"14_CR54","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/S0306-4522(98)00481-3","volume":"90","author":"JD Jentsch","year":"1999","unstructured":"Jentsch JD, Taylor JR, Elsworth JD, Redmond DE Jr, Roth RH. Altered frontal cortical dopaminergic transmission in monkeys after subchronic phencyclidine exposure: involvement in frontostriatal cognitive deficits. Neuroscience. 1999;90:823\u201332.","journal-title":"Neuroscience"},{"key":"14_CR55","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.neuroscience.2006.09.026","volume":"144","author":"SJ Kanes","year":"2006","unstructured":"Kanes SJ, Tokarczyk J, Siegel SJ, Bilker W, Abel T, Kelly MP. Rolipram: a specific phosphodiesterase 4 inhibitor with potential antipsychotic activity. Neurosci. 2006;144:239\u201346.","journal-title":"Neurosci"},{"key":"14_CR56","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1517\/13543776.2012.739157","volume":"23","author":"J Kehler","year":"2013","unstructured":"Kehler J. Phosphodiesterase 10A inhibitors: a 2009-2012 patent update. Expert Opin Ther Pat. 2013;23:31\u201345.","journal-title":"Expert Opin Ther Pat"},{"key":"14_CR57","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1517\/13543770903431050","volume":"19","author":"J Kehler","year":"2009","unstructured":"Kehler J, Kilburn JP. Patented PDE10A inhibitors: novel compounds since 2007. Expert Opin Ther Pat. 2009;19:1715\u201325.","journal-title":"Expert Opin Ther Pat"},{"key":"14_CR58","doi-asserted-by":"crossref","first-page":"8457","DOI":"10.1073\/pnas.1000730107","volume":"107","author":"MP Kelly","year":"2010","unstructured":"Kelly MP, Logue SF, Brennan J, Day JP, Lakkaraju S, Jiang L, Zhong X, Tam M, Sukoff Rizzo SJ, Platt BJ, Dwyer JM, Neal S, Pulito VL, Agostino MJ, Grauer SM, Navarra RL, Kelley C, Comery TA, Murrills RJ, Houslay MD, Brandon NJ. Phosphodiesterase 11A in brain is enriched in ventral hippocampus and deletion causes psychiatric disease-related phenotypes. Proc Natl Acad Sci U S A. 2010;107:8457\u201362.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"14_CR59","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1093\/schbul\/sbj053","volume":"32","author":"B Kirkpatrick","year":"2006","unstructured":"Kirkpatrick B, Fenton WS, Carpenter WT, Marder SR. The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull. 2006;32:214\u20139.","journal-title":"Schizophr Bull"},{"key":"14_CR60","doi-asserted-by":"crossref","first-page":"4366","DOI":"10.1074\/jbc.M308471200","volume":"279","author":"J Kotera","year":"2004","unstructured":"Kotera J, Sasaki T, Kobayashi T, Fujishige K, Yamashita Y, Omori K. Subcellular localization of cyclic nucleotide phosphodiesterase type 10A variants, and alteration of the localization by cAMP-dependent protein kinase-dependent phosphorylation. J Biol Chem. 2004;279:4366\u201375.","journal-title":"J Biol Chem"},{"key":"14_CR61","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1001\/archpsyc.1994.03950030035004","volume":"51","author":"JH Krystal","year":"1994","unstructured":"Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, Heninger GR, Bowers MB Jr, Charney DS. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans, psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiat. 1994;51:199\u2013214.","journal-title":"Arch Gen Psychiat"},{"key":"14_CR62","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1007\/s00213-011-2436-8","volume":"219","author":"M Kuroiwa","year":"2012","unstructured":"Kuroiwa M, Snyder GL, Shuto T, Fukuda A, Yanagawa Y, Benavides DR, Nairn AC, Bibb JA, Greengard P, Nishi A. A PDE4 inhibitor, rolipram, enhances dopamine D1 receptor\/PKA\/DARPP-32 signaling in cortical neurons. Psychopharmacology. 2012;219:1065\u201379.","journal-title":"Psychopharmacology"},{"key":"14_CR63","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.neuropharm.2010.05.004","volume":"59","author":"V Lakics","year":"2010","unstructured":"Lakics V, Karran EH, Boess FG. Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissues. Neuropharmacology. 2010;59:367\u201374.","journal-title":"Neuropharmacology"},{"key":"14_CR64","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1196\/annals.1300.063","volume":"1003","author":"M Laruelle","year":"2003","unstructured":"Laruelle M, Kegeles LS, Abi-Dargham A. Glutamate, dopamine, and schizophrenia: from pathophysiology to treatment. Ann N Y Acad Sci. 2003;1003:138\u201358.","journal-title":"Ann N Y Acad Sci"},{"issue":"Suppl A","key":"14_CR65","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/j.clinthera.2005.07.017","volume":"27","author":"M Laruelle","year":"2005","unstructured":"Laruelle M, Frankle WG, Narendran R, Kegeles LS, Abi-Dargham A. Mechanism of action of antipsychotic drugs: from dopamine D(2) receptor antagonism to glutamate NMDA facilitation. Clin Ther. 2005;27(Suppl A):S16\u201324.","journal-title":"Clin Ther"},{"key":"14_CR66","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/schbul\/sbq162","volume":"37","author":"T Laughren","year":"2011","unstructured":"Laughren T, Levin R. Food and Drug Administration commentary on methodological issues in negative symptom trials. Schizophr Bull. 2011;37:255\u20136.","journal-title":"Schizophr Bull"},{"key":"14_CR67","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1080\/1029842021000022089","volume":"4","author":"BK Lipska","year":"2002","unstructured":"Lipska BK, Weinberger DR. A neurodevelopmental model of schizophrenia: neonatal disconnection of the hippocampus. Neurotox Res. 2002;4:469\u201375.","journal-title":"Neurotox Res"},{"key":"14_CR68","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0378-1119(99)00171-7","volume":"234","author":"K Loughney","year":"1999","unstructured":"Loughney K, Snyder PB, Uher L, Rosman GJ, Ferguson K, Florio VA. Isolation and characterization of PDE10A, a novel human 3\u2032, 5\u2032-cyclic nucleotide phosphodiesterase. Gene. 1999;234:109\u201317.","journal-title":"Gene"},{"key":"14_CR69","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1124\/jpet.109.156729","volume":"331","author":"A Masood","year":"2009","unstructured":"Masood A, Huang Y, Hajjhussein H, Xiao L, Li H, Wang W, Hamza A, Zhan CG, O\u2019Donnell JM. Anxiolytic effects of phosphodiesterase \u22122 inhibitors associated with increased cGMP signaling. J Phamacol Exp Ther. 2009;331:690\u20139.","journal-title":"J Phamacol Exp Ther"},{"key":"14_CR70","doi-asserted-by":"publisher","unstructured":"McGirr A, Lipina TV, Mun H-S, Georgiou J, Al-Amri AH, Ng E, Zhai D, Elliott C, Cameron RT, Mullins JGL, Liu F, Baillie GS, Clapcote SJ, Roder JC. Specific inhibition of phosphodiesterase-4B results in anxiolysis and facilitates memory acquisition. Neuropsychopharmacology. 2015; doi: 10.1038\/npp.2015.240 .","DOI":"10.1038\/npp.2015.240"},{"key":"14_CR71","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0022-3565(25)20710-8","volume":"251","author":"HY Meltzer","year":"1989","unstructured":"Meltzer HY, Matsubara S, Lee JC. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D1, D2 and serotnin2 pki values. J Pharmacol Exp Ther. 1989;251:238\u201346.","journal-title":"J Pharmacol Exp Ther"},{"key":"14_CR72","first-page":"77","volume-title":"Serotonin in antipsychotic treatment: mechanisms and clinical practice","author":"HY Meltzer","year":"1996","unstructured":"Meltzer HY, Fatemi SH. The role of serotonin in schizophrenia and the mechanism of action of antipsychotic drugs. In: Kane JM, Moller H-J, Awouters F, editors. Serotonin in antipsychotic treatment: mechanisms and clinical practice. New York: Marcel Dekler; 1996. p. 77\u2013107."},{"key":"14_CR73","first-page":"54","volume":"8","author":"FS Menniti","year":"2007","unstructured":"Menniti FS, Chappie TA, Humphrey JM, Schmidt CJ. Phosphodiesterase 10A inhibitors: a novel approach to the treatment of the symptoms of schizophrenia. Curr Opin Investig Drugs. 2007;8:54\u20139.","journal-title":"Curr Opin Investig Drugs"},{"key":"14_CR74","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1126\/science.1112915","volume":"310","author":"JK Millar","year":"2005","unstructured":"Millar JK, Picard BS, Mackie S, James R, Christie S, Buchanan SR, Malloy MP, Chubb JE, Huston E, Baillie GS, Thomson PA, Hill EV, Brandon NJ, Rain JC, Camargo LM, Whiting PJ, Houslay MD, Blackwood DH, Muir WJ, Porteous DJ. DISC1 and PDE4B are interacting genetic factors in schizophrenia that regulate cAMP signaling. Science. 2005;310:1187\u201391.","journal-title":"Science"},{"key":"14_CR75","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1093\/hmg\/9.9.1415","volume":"9","author":"JK Millar","year":"2000","unstructured":"Millar JK, Wilson-Annan JC, Anderson S, Christie S, Taylor MS, Semple CA, et al. Disruption of two novel genes by a translocation co-segregating with schizophrenia. Hum Mol Genet. 2000;9:1415\u201323.","journal-title":"Hum Mol Genet"},{"key":"14_CR76","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s00213-008-1240-6","volume":"202","author":"T Nagai","year":"2009","unstructured":"Nagai T, Murai R, Matsui K, Kamei H, Noda Y, Furukawa H, Nabeshima T. Aripiprazole ameliorates phencyclidine-induced impairment of recognition memory through dopamine D1 and serotonin 5-HT1A receptors. Psychopharmacology. 2009;202:315\u201328.","journal-title":"Psychopharmacology"},{"key":"14_CR77","doi-asserted-by":"crossref","first-page":"10460","DOI":"10.1523\/JNEUROSCI.2518-08.2008","volume":"28","author":"A Nishi","year":"2008","unstructured":"Nishi A, Kuroiwa M, Miller DB, O\u2019Callaghan JP, Bateup HS, Shuto T, Sotogaku N, Fukuda T, Heintz N, Greengard P, Snyder GL. Distinct roles of PDE4 and PDE10A in the regulation of cAMP\/PKA signaling in the striatum. J Neurosci. 2008;28:10460\u201371.","journal-title":"J Neurosci"},{"key":"14_CR78","doi-asserted-by":"crossref","first-page":"3438","DOI":"10.1016\/j.bmcl.2013.03.072","volume":"23","author":"MS Plummer","year":"2013","unstructured":"Plummer MS, Cancelli J, Roark H, Skalitzky DJ, Stankovic CJ, Bove S, Pandit J, Goodman A, Hicks J, Shahripour A, Beidler D, XK L, Sanchez B, Whitehead C, Sarver R, Braden T, Gowan\u00a0R, Shen XQ, Welch K, Ogden A, Sadagopan N, Baum H, Miller H, Banotai C, Spessard C, Lightle S. Discovery of potent, selective, bioavailable phosphodiesterase 2 (PDE2) inhibitors active in an osteoarthritis pain model, part I: transformation of selective pyrazolodiazepinone phosphodiesterase (PDE4) inhibitors into selective PDE2 inhibitors. Bioorg Med Chem Lett. 2013a;23:3438\u201342.","journal-title":"Bioorg Med Chem Lett"},{"key":"14_CR79","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.1016\/j.bmcl.2013.03.082","volume":"23","author":"MS Plummer","year":"2013","unstructured":"Plummer MS, Cancelli J, Roark H, Skalitzky DJ, Stankovic CJ, Bove S, Pandit J, Goodman A, Hicks J, Shahripour A, Beidler D, XK L, Sanchez B, Whitehead C, Sarver R, Braden T, Gowan R, Shen XQ, Welch K, Ogden A, Sadagopan N, Baum H, Miller H, Banotai C, Spessard C, Lightle S. Discovery of potent selective bioavailable phosphodiesterase 2 (PDE2) inhibitors active in an osteoarthritis pain model. Part II: optimization studies and demonstration of in vivo efficacy. Bioorg Med Chem Lett. 2013b;23:3443\u20137.","journal-title":"Bioorg Med Chem Lett"},{"key":"14_CR80","doi-asserted-by":"crossref","unstructured":"Polito M, Guiot E, Gangarossa G, Longueville S, Doulazmi M, Valjent E, Herve D, Girault J-A, Paupardin-Tritsch D, Castro LV, Vincent P (2015) Selective effects of PDE10A inhibitors on striatopallidal neurons require phosphatase inhibition by DARPP-32. eNeuro DOI:http:\/\/dx,doi.org\/10.1523\/ENEURO.0060-15.2015.","DOI":"10.1523\/ENEURO.0060-15.2015"},{"key":"14_CR81","doi-asserted-by":"crossref","first-page":"11079","DOI":"10.1073\/pnas.89.22.11079","volume":"89","author":"JW Polli","year":"1992","unstructured":"Polli JW, Kincaid RL. Molecular cloning of DNA encoding a calmodulin-dependent phosphodiesterase enriched in striatum. Proc Natl Acad Sci U S A. 1992;89:11079\u201383.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"14_CR82","doi-asserted-by":"crossref","first-page":"72","DOI":"10.2174\/1871524914666141226103421","volume":"14","author":"AD Ramirez","year":"2014","unstructured":"Ramirez AD, Smith SM. Regulation of dopamin esignaling in the striatum by phosphodiesterase inhibitors: novel therapeutics to treat neurological and psychiatric disorders. Cent Nerv Syst Agents Med Chem. 2014;14:72\u201382.","journal-title":"Cent Nerv Syst Agents Med Chem"},{"key":"14_CR83","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ejphar.2015.04.040","volume":"761","author":"JP Redrobe","year":"2015","unstructured":"Redrobe JP, Rasmussen LK, Christoffersen CT, Bundgaard C, J\u00f8rgensen M. Characterisation of lu AF33241: a novel, brain-permeant, dual inhibitor of phosphodiesterase (PDE)2A and PDE10A. Eur J Pharmacol. 2015;761:79\u201385.","journal-title":"Eur J Pharmacol"},{"key":"14_CR84","doi-asserted-by":"crossref","first-page":"5188","DOI":"10.1523\/JNEUROSCI.22-12-05188.2002","volume":"22","author":"TM Reed","year":"2002","unstructured":"Reed TM, Repaske DR, Snyder GL, Greengard P, Vorhees CV. Phosphodiesterase 1B knock-out mice exhibit exaggerated locomotor hyperactivity and DARPP-32 phosphorylation in response to dopamine agonists and display impaired spatial learning. J Neurosci. 2002;22:5188\u201397.","journal-title":"J Neurosci"},{"key":"14_CR85","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s00213-008-1273-x","volume":"202","author":"OA Reneerkens","year":"2009","unstructured":"Reneerkens OA, Rutten K, Steinbusch HW, Blokland A, Prickaerts J. Selective phosphodiesterase inhibitors: a promising target for cognition enhancement. Psychopharmacology. 2009;202:419\u201343.","journal-title":"Psychopharmacology"},{"key":"14_CR86","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.bbr.2012.08.019","volume":"236","author":"OAH Reneerkens","year":"2013","unstructured":"Reneerkens OAH, Rutten K, Bollen E, Hage T, Blokland A, HWM S, Prickaerts J. Inhibition of phosphodiesterase type 2 or type 10 reverses object memory deficits induced by scopolamine or MK-801. Behav Brain Res. 2013;236:16\u201322.","journal-title":"Behav Brain Res"},{"key":"14_CR87","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/S0028-3908(00)00142-8","volume":"40","author":"A Robichaud","year":"2001","unstructured":"Robichaud A, Savoie C, Stamatiou PB, Tattersall FD, Chan C. PDE4 inhibitors induce emesis in ferrets via a noradrenergic pathway. Neuropharmacology. 2001;40:262\u20139.","journal-title":"Neuropharmacology"},{"key":"14_CR88","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1111\/j.1460-9568.2005.03937.x","volume":"21","author":"JS Rodefer","year":"2005","unstructured":"Rodefer JS, Murphy ER, Baxter MG. PDE10A inhibition reverses subchronic PCP-induced deficits in attentional set-shifting in rats. Eur J Neurosci. 2005;21:1070\u20136.","journal-title":"Eur J Neurosci"},{"key":"14_CR89","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ejphar.2006.11.041","volume":"558","author":"K Rutten","year":"2007","unstructured":"Rutten K, Prickaerts J, Hendrix M, van der Staay FJ, Sik A, Blokland A. Time-dependent involvement of cAMP and cGMP in consolidation of object memory: studies using selective phosphodiesterase type 2, 4, and 5 inhibitors. Eur J Pharmacol. 2007;558:107\u201312.","journal-title":"Eur J Pharmacol"},{"key":"14_CR90","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/j.1460-9568.2008.06349.x","volume":"28","author":"K Rutten","year":"2008","unstructured":"Rutten K, Misner DL, Works M, Blokland A, Novak TJ, Santarelli L, Wallace TL. Enhanced long-term potentiation and impaired learning in phosphodiesterase 4D-knockout (PDE4D \u2212\/\u2212 ) mice. Eur J Neurosci. 2008;28:625\u201332.","journal-title":"Eur J Neurosci"},{"key":"14_CR91","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1126\/science.1825731","volume":"251","author":"T Sawaguchi","year":"1991","unstructured":"Sawaguchi T, Goldman-Rakic PS. D1 dopamine receptors in prefrontal cortex: involvement in working memory. Science. 1991;251:947\u201350.","journal-title":"Science"},{"key":"14_CR92","doi-asserted-by":"crossref","unstructured":"Schmidt CJ, Chapin DS, Cianfrogna J, Corman ML, Hajos M, Harms JF, Hoffman WE, Lebel LA, McCarthy SA, Nelson FR, Proulx-LaFrance C, Majchrzak MJ, Ramirez AD, Schmidt K, Seymour PA, Siuciak JA, Tingley FD 3rd, Williams RD, Verhoest PR, Menniti FS. Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia. J Pharmacol Exp Ther. 2008;325:681\u201390.","DOI":"10.1124\/jpet.107.132910"},{"key":"14_CR93","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3389\/fphar.2012.00195","volume":"3","author":"TL Schwartz","year":"2012","unstructured":"Schwartz TL, Sachdeva S, Stahl SM. Glutamate neurocircuitry: theoretical underpinnings in schizophrenia. Front Pharmacol. 2012;3:195.","journal-title":"Front Pharmacol"},{"key":"14_CR94","doi-asserted-by":"crossref","unstructured":"Seeger TF, Bartlett B, Coskran TM, Culp JS, James LC, Krull DL, Lanfear J, Ryan AM, Schmidt CJ, Strick CA, Varghese AH, Williams RD, Wylie PG, Menniti FS. Immunohistochemical localization of PDE10A in the rat brain. Brain Res. 2003;985:113\u201326.","DOI":"10.1016\/S0006-8993(03)02754-9"},{"key":"14_CR95","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.schres.2015.11.015","volume":"170","author":"S Shim","year":"2016","unstructured":"Shim S, Shuman M, Duncan E. An emerging role of cGMP in the treatment of schizophrenia: a review. Schizophr Res. 2016;170:226\u201331.","journal-title":"Schizophr Res"},{"key":"14_CR96","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.neuropharm.2012.06.048","volume":"64","author":"AS Sierksma","year":"2013","unstructured":"Sierksma AS, Rutten K, Sydlik S, Rosamian S, Steinbusch HW, van den Hove DL, Prickaerts J. Chronic phosphodiesterase type 2 inhibition improves memory in the APPswe\/PS1dE9 mouse model of Alzheimer\u2019s disease. Neuropharmacology. 2013;64:124\u201336.","journal-title":"Neuropharmacology"},{"key":"14_CR97","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.neuron.2010.02.014","volume":"65","author":"EH Simpson","year":"2010","unstructured":"Simpson EH, Kellendonk C, Kandel E. A possible role for the striatum in the pathogenesis of the cognitive symptoms of schizophrenia. Neuron. 2010;65:585\u201396.","journal-title":"Neuron"},{"key":"14_CR98","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.neuropharm.2006.04.013","volume":"51","author":"JA Siuciak","year":"2006","unstructured":"Siuciak JA, Chapin DS, Harms JF, Lebel LA, SA MC, Chambers L, Shrikhande A, Wong S, Menniti FS, Schmidt CJ. Inhibition of the striatum-enriched phosphodiesterase PDE10A: a novel approach to the treatment of psychosis. Neuropharmacology. 2006;51:386\u201396.","journal-title":"Neuropharmacology"},{"key":"14_CR99","doi-asserted-by":"crossref","unstructured":"Siuciak JA, Chapin DS, McCarthy SA, Martin AN. Antipsychotic profile of rolipram: efficacy in rats and reduced sensitivity in mice deficient in the phosphodiesterase-4B (PDE4B) enzyme. Psychopharmacology. 2007a;192:415\u201324.","DOI":"10.1007\/s00213-007-0727-x"},{"key":"14_CR100","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s00213-007-1014-6","volume":"197","author":"JA Siuciak","year":"2008","unstructured":"Siuciak JA, McCarthy SA, Chapin DS, martin AN. Behavioral and neurochemical characterization of mice deficient in the phosphodiesterase-4B (PDE4B) enzyme. Psychopharmacology. 2008;197:115\u201326.","journal-title":"Psychopharmacology"},{"key":"14_CR101","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.neuropharm.2007.04.009","volume":"53","author":"JA Siuciak","year":"2007","unstructured":"Siuciak JA, McCarthy SA, Chapin DS, Teed TM, Vorhees CV, Repaske DR. Behavioral and neurochemical characterization of mice deficient in the phosphodiesterase-1B (PDE1B) enzyme. Neuropharmacology. 2007b;53:113\u201324.","journal-title":"Neuropharmacology"},{"key":"14_CR102","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.neuropharm.2012.06.013","volume":"64","author":"SM Smith","year":"2013","unstructured":"Smith SM, Uslaner JM, Cox CD, Huszar SL, Cannon CE, Vardigan JD, et al. The novel phosphodiesterase 10A inhibitor THPP-1 has antipsychotic-like effects in rat and improves cognition in rat and rhesus monkey. Neuropharmacology. 2013;64:215\u201323.","journal-title":"Neuropharmacology"},{"key":"14_CR103","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s00213-014-3704-1","volume":"232","author":"GL Snyder","year":"2014","unstructured":"Snyder GL, Vanover KE, Zhu H, Miller DB, O-Callaghan JP, Tomesch J, Li P, Zhang Q, Krishnan V, Hendrick JP Jr, Nestler EJ, Davis RE, Wennogle LP, Mates S. Functional profile of a novel modulator of serotonin, dopamine, and glutamate neurotransmission. Psychopharmacology. 2014;232:605\u201321.","journal-title":"Psychopharmacology"},{"issue":"17","key":"14_CR104","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1007\/s00213-016-4346-2","volume":"233","author":"GL Snyder","year":"2016","unstructured":"Snyder GL, Prickaerts J, Wadenberg ML, Zhang L, Zheng H, Yao W, Akkerman S, Zhu H, Hendrick JP, Vanover KE, Davis R, Li P, Mates S, Wennogle LP. Preclinical profile of ITI-214, an inhibitor of phosphodiesterase 1, for enhancement of memory performance in rats. Psychopharmacology. 2016;233(17):3113\u201324.","journal-title":"Psychopharmacology"},{"key":"14_CR106","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S0021-9258(18)54200-9","volume":"268","author":"WK Sonnenburg","year":"1993","unstructured":"Sonnenburg WK, Seger D, Beavo JA. Molecular cloning of a cDNA encoding the \"61-kDa\" calmodulin-stimulated cyclic nucleotide phosphodiesterase. Tissue-specific expression of structurally related isoforms. J Biol Chem. 1993;268:645\u201352.","journal-title":"J Biol Chem"},{"key":"14_CR107","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1369\/jhc.2009.953471","volume":"57","author":"DT Stephenson","year":"2009","unstructured":"Stephenson DT, Coskran TM, Wilhelms MB, Adamowicz WO, O\u2019Donnell MM, Muravnick KB, Menniti FS, Kleiman RJ, Morton D. Immunohistochemical localization of phosphodiesterase 2A in multiple mammalian species. J Histochem Cytochem. 2009;57:933\u201349.","journal-title":"J Histochem Cytochem"},{"key":"14_CR108","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.neuroscience.2012.09.011","volume":"226","author":"DT Stephenson","year":"2012","unstructured":"Stephenson DT, Coskran TM, Kelly MP, Kleiman RJ, Morton D, O\u2019Neill SM, Schmidt CJ, Weinberg RJ, Menniti FS. The distribution of phosphodiesterase 2A in the rat brain. Neuroscience. 2012;226:145\u201355.","journal-title":"Neuroscience"},{"issue":"Suppl 3","key":"14_CR109","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1097\/00004850-199803003-00004","volume":"13","author":"CA Tamminga","year":"1998","unstructured":"Tamminga CA, Buchanan RW, Gold JM. The role of negative symptoms and cognitive dysfunction in schizophrenia outcome. Int Clin Psychopharmacol. 1998;13(Suppl 3):S21\u20136.","journal-title":"Int Clin Psychopharmacol"},{"key":"14_CR110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.schres.2009.03.005","volume":"110","author":"R Tandon","year":"2009","unstructured":"Tandon R, Nasrallah HA, Keshavan MS. Schizophrenia. \u201cjust the facts\u201d 4. Clinical features and conceptualization. Schizophr Res. 2009;110:1\u201312.","journal-title":"Schizophr Res"},{"key":"14_CR0110","unstructured":"Targum SD, Keefe RS. Cognition and schizophrenia: is there a role for cognitive assessments in diagnosis and treatment? Psychoiatry (Edgmont). 2008;5:55\u20139."},{"key":"14_CR111","doi-asserted-by":"crossref","first-page":"RC23","DOI":"10.1523\/JNEUROSCI.19-18-j0001.1999","volume":"19","author":"JR Taylor","year":"1999","unstructured":"Taylor JR, Birnbaum S, Ubriani R, Arnsten AF. Activation of cAMP-dependent protein kinase a in prefrontal cortex impairs working memory performance. J Neurosci. 1999;19:RC23.","journal-title":"J Neurosci"},{"key":"14_CR112","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1124\/jpet.108.146332","volume":"328","author":"S Threlfell","year":"2009","unstructured":"Threlfell S, Sammut S, Menniti FS, Schmidt CJ, West AR. Inhibition of phosphodiesterase 10A increases the responsiveness of striatal projections neurons to cortical stimulation. J Pharmacol Exp Ther. 2009;328:785\u201395.","journal-title":"J Pharmacol Exp Ther"},{"key":"14_CR113","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.pharmthera.2015.06.008","volume":"153","author":"EM Tsapakis","year":"2015","unstructured":"Tsapakis EM, Dimopoulou T, Tarazi F. Clinical management of negative symptoms of schizophrenia: an update. Pharmacol Ther. 2015;153:135\u201347.","journal-title":"Pharmacol Ther"},{"key":"14_CR114","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.neuropharm.2008.07.005","volume":"55","author":"FJ Staay Van der","year":"2008","unstructured":"Van der Staay FJ, Rutten K, B\u00e4rkacker L, Devry J, Erb C, Heckroth H, Karthaus D, Tersteegen A, van Kampen M, Blokland A, Prickaerts J, Teymann KG, Schr\u00f6der UH, Hendrix M. The novel selective PDE9 inhibitor BAY 73-6991 improves learning and memory in rodents. Neuropharmacology. 2008;55:908\u201318.","journal-title":"Neuropharmacology"},{"key":"14_CR115","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1023\/A:1025704031210","volume":"31","author":"WCG Staveren Van","year":"2002","unstructured":"Van Staveren WCG, Glick J, Markerink-van Ittersum M, Shimizu M, Beavo JA, Steinbusch HWM, DeVente J. Cloning and localization of the cGMP-specific phosphodiesterase 9 in the rat brain. J Neurocyt. 2002;31:729\u201341.","journal-title":"J Neurocyt"},{"key":"14_CR116","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S0149-7634(99)00037-8","volume":"23","author":"ML Wadenberg","year":"1999","unstructured":"Wadenberg ML, Hicks PB. The conditioned avoidance response test re-evaluated: is it a sensitive test for the detection of potentially atypical antipsychotics? Neurosci Biobehav Rev. 1999;23:851\u201362.","journal-title":"Neurosci Biobehav Rev"},{"key":"14_CR117","first-page":"243","volume":"1","author":"SI Walaas","year":"1989","unstructured":"Walaas SI, Girault JA, Greengard P. Localization of cyclic GMP-dependent protein kinase in rat basal ganglia neurons. J Mol Neurosci. 1989;1:243\u201350.","journal-title":"J Mol Neurosci"},{"key":"14_CR118","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/(SICI)1098-2396(199605)23:1<20::AID-SYN3>3.0.CO;2-J","volume":"23","author":"AR West","year":"1996","unstructured":"West AR, Galloway MP. Regulation of serotonin-facilitated dopamine release in vivo: the role of protein kinase a activating transduction mechanisms. Synapse. 1996;23:20\u20137.","journal-title":"Synapse"},{"key":"14_CR119","doi-asserted-by":"crossref","first-page":"378","DOI":"10.2174\/1381612820666140826114744","volume":"21","author":"LS Wilson","year":"2015","unstructured":"Wilson LS, Brandon NJ. Emerging biology of PDE10A. Curr Pharm Des. 2015;21:378\u201388.","journal-title":"Curr Pharm Des"},{"key":"14_CR120","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.neuropharm.2015.08.008","volume":"99","author":"JM Wilson","year":"2015","unstructured":"Wilson JM, Ogden AML, Loomis S, Gilmour G, Baucum IIAJ, Belecky-Adams TL, Merchant KM. Phosphodiesterase 10A inhibitor, MP-10 (PF-2545920), produces greater induction of c-Fos in dopamine D2 neurons than in D1 neurons in neostriatum. Neuropharmacology. 2015;99:379\u201386.","journal-title":"Neuropharmacology"},{"key":"14_CR121","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.neuroscience.2005.09.028","volume":"139","author":"GV Williams","year":"2006","unstructured":"Williams GV, Castner SA. Under the curve: critical issues for elucidating D1 receptor function in working memory. Neurosci. 2006;139:263\u201376.","journal-title":"Neurosci"},{"issue":"6","key":"14_CR122","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/nrn1406","volume":"5","author":"RA Wise","year":"2004","unstructured":"Wise RA. Dopamine, learning and motivation. Nat Rev Neurosci. 2004;5(6):483\u201394.","journal-title":"Nat Rev Neurosci"},{"key":"14_CR123","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.neuroscience.2005.12.042","volume":"139","author":"Z Xie","year":"2006","unstructured":"Xie Z, Adamowicz WO, Eldred WD, Jakowski AB, Kleiman RJ, Morton DG, et al. Cellular and subcellular localization of PDE10A, a striatum-enriched phosphodiesterase. Neuroscience. 2006;139:597\u2013607.","journal-title":"Neuroscience"},{"key":"14_CR124","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1017\/S146114571200065X","volume":"16","author":"Y Xu","year":"2013","unstructured":"Xu Y, Pan J, Chen L, Zhang C, Sun J, Li J, Nguyen L, Nair N, Zhang H, O'Donnell JM. Phosphodiesterase-2 inhibitor reverses corticosterone-induced neurotoxicity and related behavioural changes via cGMP\/PKG dependent pathway. Int J Neuropsychopharmacol. 2013;16:835\u201347.","journal-title":"Int J Neuropsychopharmacol"},{"key":"14_CR125","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.neurobiolaging.2014.08.028","volume":"36","author":"Y Xu","year":"2015","unstructured":"Xu Y, Pan J, Sun J, Ding L, Ruan L, Reed M, Yu X, Klabnik J, Lin D, Li J, Chen L, Zhang C, Zhang H, O\u2019Donnell JM. Inhibition of phosphodiesterase 2 reverses impaired cognition and neuronal remodeling caused by chronic stress. Neurobio Aging. 2015;36:955\u201370.","journal-title":"Neurobio Aging"},{"key":"14_CR126","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1254\/jjp.75.91","volume":"75","author":"N Yamashita","year":"1997","unstructured":"Yamashita N, Miyashiro M, Baba J, Sawa A. Rolipram, a selective inhibitor of phosphodiesterase type 4, pronouncedly enhanced the forskolin-induced promotion of dopamine biosynthesis in primary cultured rat mesencephalic neurons. Jpn J Pharmacol. 1997;75:91\u20135.","journal-title":"Jpn J Pharmacol"},{"key":"14_CR127","doi-asserted-by":"crossref","first-page":"9677","DOI":"10.1073\/pnas.92.21.9677","volume":"92","author":"C Yan","year":"1995","unstructured":"Yan C, Zhao AZ, Bentley JK, Loughney K, Ferguson K, Beavo JA. Molecular cloning and characterization of a calmodulin-dependent phosphodiesterase enriched in olfactory sensory neurons. Proc Natl Acad Sci U S A. 1995;92:9677\u201381.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"14_CR128","doi-asserted-by":"crossref","first-page":"4440","DOI":"10.1046\/j.1432-1327.2001.02366.x","volume":"268","author":"K Yuasa","year":"2001","unstructured":"Yuasa K, Ohgaru T, Asahina M, Omori K. Identification of rat cyclic nucleotide phosphodiesterase 11A (PDE11A): comparison of rat and human PDE11A splicing variants. Eur J Biochem. 2001;268:4440\u20138.","journal-title":"Eur J Biochem"},{"key":"14_CR129","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1038\/sj.npp.1301537","volume":"33","author":"HT Zhang","year":"2008","unstructured":"Zhang HT, Huang Y, Masood A, Stolinski LR, Li Y, Zhang L, Dlaboga D, Jin SLC, Conti M, O\u2019Donnell JM. Anxiogenic-like behavioral phenotype of mice deficient in phosphodiesterase 4B- (PDE4B). Neuropsychopharmacology. 2008;33:1611\u201323.","journal-title":"Neuropsychopharmacology"}],"container-title":["Advances in Neurobiology","Phosphodiesterases: CNS Functions and Diseases"],"original-title":[],"link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-319-58811-7_14","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T22:35:49Z","timestamp":1750890949000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-3-319-58811-7_14"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"ISBN":["9783319588094","9783319588117"],"references-count":129,"URL":"https:\/\/doi.org\/10.1007\/978-3-319-58811-7_14","relation":{},"ISSN":["2190-5215","2190-5223"],"issn-type":[{"value":"2190-5215","type":"print"},{"value":"2190-5223","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017]]}}}